TrialThe oncologist2026

Multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent chemoradiotherapy in Chinese patients with high-risk rectal cancer.

Rashid N Lui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.